Briefly, the criteria restrict to short variants that are (i) detected in 24 cancer susceptibility genes (ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2, and VHL), (ii) have a variant allele fraction (VAF) above designated thresholds for tissue CGP (≥10%) or liquid CGP (≥30%), respectively, and (iii) are classified as germline P/LP in ClinVar with a sufficient level of evidence (See “Materials and Methods”, Supplementary Table S2). This evidence concerns the gene RET and cancer.